Long-term Microphysiological Sample Imaging for Evaluation of Polypharmacy in Liverbroad
DeLIVERY · Horizon Europe grant · 2022-05-01–2026-04-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2021-PATHFINDEROPEN-01-01. CORDIS record →
Objective
DeLIVERY aims to build a radically new technology for personalized health care, which provides, for the first time, the possibility to investigate polypharmacy on individual patients. Polypharmacy is the effect that the many combinations and permutations of drug mixtures which are typically prescribed to the chronically sick or the elderly population (e.g. painkillers, beta blockers, blood thinners, anti-depressants, and statins) have on the human body. Polypharmacy is becoming a major issue in the ageing population, as well over 10% of hospital admissions for people over 60 years of age are due to currently unknown interactions of the multiple drugs being prescribed by the specialized physicians and general practitioners routinely visited by the elderly. Currently, no single platform exists that can be utilized in a highly parallelized fashion to monitor such effects at the cellular and tissue level. DeLIVERY will provide an integrated microphysiological system (MPS) culture and microscopic imaging platform specifically for the purpose of maintaining, treating and long-term imaging of patient-specific cells within their microenvironment. This MPS platform will allow physicians, biomedical scientists, and researchers to determine the individual response of human tissue biopsies to a combination of multiple drugs. DeLIVERY will enable individualized treatment options providing essential tools towards a better quality of life for older people by allowing improved personalized healthcare. Novel medicines with the potential to reverse the effects of ageing and non-alcoholic fatty liver disease (NAFLD) will be tested within typical polypharmacy contexts to determine possible interactions, and the DeLIVERY MPS system will be the purpose-built platform to provide this service. Such a system also requires a paradigm shift in microscopy - away from the single, bulky instrument providing one imaging modality towards compact and modular, yet still high-end, devices.
Beneficiaries (7)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| UNIVERSITAET BIELEFELD | DE | coordinator | €756,748 | |
| CHERRY BIOTECH | FR | participant | €870,430 | Yes |
| UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET | NO | participant | €568,009 | |
| THE HENRYK NIEWODNICZANSKI INSTITUTE OF NUCLEAR PHYSICS, POLISH ACADEMY OF SCIENCES | PL | participant | €498,750 | |
| VRIJE UNIVERSITEIT BRUSSEL | BE | participant | €430,595 | |
| EXCELITAS PCO GMBH | DE | participant | €213,750 | |
| EVANGELISCHES KLINIKUM BETHEL GGMBH | DE | participant | €208,764 |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.